StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.17−0.04 (-0.12%)

Close on Nov 18, 2026Market cap $6.85BP/E –Yield –

Immunovant free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Immunovant's free cash flow for the twelve months ending Mar 31, 2026 was -$407.32M. For fiscal 2026 it was -$407.32M. The highest annual figure on record is -$28.60M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$407.32M–
FY2025Mar 31, 2025-$376.63M–
FY2024Mar 31, 2024-$214.59M–
FY2023Mar 31, 2023-$188.39M–
FY2022Mar 31, 2022-$106.37M–
FY2021Mar 31, 2021-$83.54M–
FY2020Mar 31, 2020-$53.39M–
FY2019Mar 31, 2019-$28.60M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ1 2026Mar 31, 2026-$95.07M–
Q3 FY2026CQ4 2025Dec 31, 2025-$92.33M–
Q2 FY2026CQ3 2025Sep 30, 2025-$102.52M–
Q1 FY2026CQ2 2025Jun 30, 2025-$117.41M–
Q4 FY2025CQ1 2025Mar 31, 2025-$110.84M–
Q3 FY2025CQ4 2024Dec 31, 2024-$100.57M–
Q2 FY2025CQ3 2024Sep 30, 2024-$88.84M–
Q1 FY2025CQ2 2024Jun 30, 2024-$76.38M–
Q4 FY2024CQ1 2024Mar 31, 2024-$59.85M–
Q3 FY2024CQ4 2023Dec 31, 2023-$47.23M–
Q2 FY2024CQ3 2023Sep 30, 2023-$60.09M–
Q1 FY2024CQ2 2023Jun 30, 2023-$47.42M–
Q4 FY2023CQ1 2023Mar 31, 2023-$55.82M–
Q3 FY2023CQ4 2022Dec 31, 2022-$46.49M–
Q2 FY2023CQ3 2022Sep 30, 2022-$20.22M–
Q1 FY2023CQ2 2022Jun 30, 2022-$65.86M–
Q4 FY2022CQ1 2022Mar 31, 2022-$33.07M–
Q3 FY2022CQ4 2021Dec 31, 2021-$31.97M–
Q2 FY2022CQ3 2021Sep 30, 2021-$20.09M–
Q1 FY2022CQ2 2021Jun 30, 2021-$21.23M–
Q4 FY2021CQ1 2021Mar 31, 2021-$22.59M–
Q3 FY2021CQ4 2020Dec 31, 2020-$22.84M–
Q2 FY2021CQ3 2020Sep 30, 2020-$24.26M–
Q1 FY2021CQ2 2020Jun 30, 2020-$13.85M–
Q4 FY2020CQ1 2020Mar 31, 2020-$27.49M–
Q1 FY2020CQ2 2019Jun 30, 2019-$8.33M–
Q4 FY2019CQ1 2019Mar 31, 2019-$450–

More Immunovant figures

See a number that looks wrong?